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Metabolic disorders including obesity, type 2 diabetes, and atherosclerosis have been viewed historically as
lipid storage disorders brought about by overnutrition. It is now widely appreciated that chronic low-grade
inflammation plays a key role in the initiation, propagation, and development of metabolic diseases. Consis-
tent with its central role in coordinating inflammatory responses, numerous recent studies have implicated
the transcription factor NF-kB in the development of such diseases, thereby further establishing inflamma-
tion as a critical factor in their etiology and offering hope for the development of new therapeutic approaches
for their treatment.Introduction
The competing need to protect the body from infection while
maintaining proper energymetabolism represents a fundamental
physiological challenge. Mounting an immune response to infec-
tion is energy intensive but essential for life (Demas et al., 1997;
Romanyukha et al., 2006). Both immunity to disease and
economical use of energy reserves have been heavily favored
throughout human evolution. Yet in the modern era, when over-
nutrition is more common than starvation, metabolic diseases
have become the leading cause of deaths in the United States,
with an incidence skyrocketing worldwide. Furthermore, as the
risk of infectious diseases recedes, an immune system poised
to respond vigorously to all inflammatory challenges has itself
become a threat. Indeed, inappropriate triggering of such
responses may account for the prevalence of inflammatory
diseases such as allergy, asthma, diabetes, and cancer.
Metabolic syndrome encompasses a cluster of conditions that
result from nutrient excess, hyperglycemia, hyperlipidemia,
insulin resistance, obesity, and hepatic steatosis, which together
affect a quarter of Americans adults and over a million children
(Iyer et al., 2010). Metabolic diseases track together, and obese
patients are at increased risk for type 2 diabetes, while insulin-
resistant patients frequently suffer from cardiovascular diseases
such as atherosclerosis. This review will examine the role of
inflammatory signaling pathways in metabolic diseases,
focusing on the central regulator of inflammation, nuclear factor
kB (NF-kB). The NF-kB pathway unites the inflammatory and
metabolic responses and, as a well-studied mediator of inflam-
mation and immunity, represents an entry point for better under-
standing metabolic diseases with an eye toward developing
novel treatment strategies.
NF-kB Directs the Inflammatory Response
The transcription factor NF-kB promotes immunity by controlling
the expression of genes involved in inflammation (http://www.nf-
kb.org/target/index.html). Cytokines and pathogen-associated
molecular patterns (PAMPs) stimulate cell surface receptors
including toll-like receptors (TLRs) to initiate a signaling cascade
resulting in the activation of NF-kB. NF-kB drives expression of
target genes that mediate cell proliferation and release of antimi-
crobial molecules and cytokines to activate the immune
response (Hayden and Ghosh, 2008). Although NF-kB was firstcharacterized in cells of the hematopoietic system, subsequent
research has revealed that NF-kB activation can occur in most
cell types. Indeed, a number of recent high-profile reports have
demonstrated a key role for the NF-kB signaling pathway in
the liver, adipose tissue, and central nervous system in the devel-
opment of inflammation-associated metabolic diseases.
NF-kB Activation in Macrophages Initiates
the Inflammatory Cascade
Microbial infection or damage to the tissue triggers an inflamma-
tory response characterized by an influx of white blood cells,
redness, pain, swelling, and, ultimately, organ dysfunction.
Macrophages, mononuclear phagocytic leukocytes, provide
a first line of defense against invading microorganisms by orga-
nizing the inflammatory response. The inflammatory cascade
begins when recognition of PAMPs by local cells results in the
release of cytokines that cause blood vessels to display
adhesion molecules that promote entry of leukocytes into the
tissue. Local cytokines activate NF-kB to promote macrophage
relocalization and activation at the site of infection. Activated
macrophages produce antimicrobial molecules and release
chemokines and cytokines to augment macrophage activation
and recruitment to the tissue. Together, antimicrobial molecules
and recruited leukocytes cooperate to kill pathogens, clear
infection, and remove dead cells. Termination of the inflamma-
tory response is vital to maintain overall health, as chronic
macrophage activation is associated with rheumatoid arthritis,
type 2 diabetes and atherosclerosis (Baumgartl et al., 2006;
Jimi et al., 2004; Rocha and Libby, 2009).
The IKK Complex Regulates NF-kB Activation
NF-kB activity is under the control of signaling from extracellular
stimuli (Figure 1). Inhibitor of kB (IkB)molecules sequester NF-kB
in the cytosol of resting cells and prevent its nuclear localization
and transcriptional function. Cytokine or PAMP ligation of cell
surface receptors initiates signaling cascades that converge on
the activation of the inhibitor of kB kinase (IKK) complex (Hayden
and Ghosh, 2008). IKK phosphorylation of IkB molecules
promotes their degradation and releases NF-kB, which translo-
cates to the nucleus to promote transcription of target genes.
The IKK complex consists of three subunits: the catalytic
subunits IKKa(IKK1) and IKKb(IKK2) and the regulatory subunit
NEMO(IKKg). Extensive research has defined IKKb and NEMO
as essential mediators of the inflammatory and immuneCell Metabolism 13, January 5, 2011 ª2011 Elsevier Inc. 11
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Figure 1. Inflammatory Triggers Activate Expression of
Proinflammatory Genes through IKK and NF-kB
After engagement of Toll-like receptors and cytokine receptors, signaling
through MyD88 and death domain adaptor molecules (respectively) and
then via TRAFs results in phosphorylation of IKK and activation of the IKK
complex kinase activity. NF-kB is constitutively bound to IkBmolecules which
confine its localization to the cytosol. IKK complex phosphorylation of serine
residues on IkB promotes its polyubiquitination and degradation, thereby
freeing NF-kB to enter the nucleus and activate transcription of target genes.
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life, as IKK mediates multiple essential pathways including cell
survival and metabolic functions described later in this review.
NF-kB Regulates Inflammation through
Cytokine-Directed Cell Differentiation
NF-kB regulated genes direct the differentiation of distinct
immune cell types. Macrophage cells differentiate from mono-
cytes after recruitment to sites of infection and exposure to the
local cytokine milieu (Mantovani et al., 2005). Differentiated
macrophages can be categorized into two broad types based
both on function and cytokine expression. M1 macrophages
produce IL-1, IL-6, TNF-a, and other proinflammatory cytokines
and, as a result, mobilize neutrophils and help initiate the innate
immune response to pathogens. These and other NF-kB-driven
cytokines produced by M1 macrophages also activate lympho-
cytes and communicate infection to the adaptive immune
system. T lymphoctyes are stimulated by proinflammatory
cytokines and ligands specific for their individual T cell antigen
receptors (TCRs). Activated T cells proliferate and release
more cytokines, including IFN-g, IL-6, and TNF-a, further driving12 Cell Metabolism 13, January 5, 2011 ª2011 Elsevier Inc.differentiation of M1macrophages, recruitment of more lympho-
cytes, and initiation of the adaptive immune response. Both
T cells andM1macrophages are associated with chronic inflam-
mation in metabolic diseases, and have been found to accumu-
late in the adipose tissue of obese mice and in the liver and
pancreas of mice with insulin resistance (Weisberg et al., 2003).
A second class of macrophages, M2, participates in wound
healing responses. M2 macrophages secrete the anti-inflamma-
tory cytokine IL-10. IL-10 is also released by CD4+Foxp3+ regu-
latory T cells (Tregs). Tregs and M2 macrophages reside in the
adipose tissue of lean mice and in healthy peripheral tissues of
insulin-responsive animals. NF-kB-dependent differentiation of
monocytes into either M1 or M2 macrophages, in response to
cytokines produced by lymphocytes and other immune cells, is
a critical factor in the development of inflammatory metabolic
diseases. Therefore, NF-kB regulates expression of the inflam-
matory mediators that recruit monocytes, drive differentiation
tomacrophages, and direct macrophage cell fate determination,
further involving NF-kB in inflammation-associated metabolic
disease.
Downregulation of the Immune Response and Chronic
Inflammation
Both cell-intrinsic and cell-extrinsic mechanisms work in a coor-
dinated manner to regulate the inflammatory response. Among
cell-extrinsic mechanisms, the short half-life of proinflammatory
cytokines limits the duration of the inflammatory response. The
anti-inflammatory cytokine IL-10 counters immune cell activa-
tion and attenuates the inflammatory response. After release of
antimicrobial molecules, macrophages clear dead cells by
phagocytosis to prevent tissue necrosis. By removing dead
cells, macrophages eliminate the source of proinflammatory
mediators at the cellular level.
Cell-intrinsic regulatory mechanisms are many and include
those that attenuate the NF-kB inflammatory gene program.
Numerous negative regulators of NF-kB have been identified
(Hayden and Ghosh, 2008). For example, de novo synthesis of
IkB molecules directly reinstates control over NF-kB in the
cytosol and the deubiqutinase A20 targets upstream compo-
nents of the NF-kB signaling pathway. Interestingly, both A20
and IkBs are targets of NF-kB transcriptional activity, indicating
that the NF-kB transcriptional program induces its own signal
decay and termination. Specificity within this process helps to
fine tune responses and limit deleterious effects. Thus, rather
than representing a global shutdown of NF-kB, selective inacti-
vation of the transcription allows continued expression of antimi-
crobial effectors while limiting tissue destruction resulting from
unchecked inflammation (Foster et al., 2007).
Both cell-extrinsic and -intrinsic mechanisms are dysregu-
lated under conditions of chronic inflammatory disease. Macro-
phages recruited to clear away dead cells can themselves be
activated by local cells to produce proinflammatory mediators.
Indeed, successive cycles of cell death, macrophage recruit-
ment, and activation and release of IL-6 and TNF-a can lead to
a state of chronic unresolved inflammation. Uncoupling NF-kB
from its intracellular negative regulatory networks by knocking
out A20, or by enforced expression of a constitutively active
IKK complex, has been associated with arthritis, type-2 dia-
betes, atherosclerosis, and cancer (Idel et al., 2003; Lee et al.,
2000; Wolfrum et al., 2007).
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pate in the development of multiple metabolic diseases.
A number of recent high-profile reports have demonstrated
a requirement for components of the NF-kB signaling apparatus
in the development of metabolic disease in genetic mouse
models. This review will summarize the recent literature and
highlight unanswered questions regarding the role of NF-kB in
three common metabolic disorders: obesity, insulin resistance,
and atherosclerosis.
Inflammation and Obesity
Sixty-five percent of American adults are overweight or obese
and face decreased life expectancy and numerous additional
health risks as a result, including dementia, degenerative neuro-
logical disease, airway disease, insulin resistance, type 2 dia-
betes, cardiovascular disease, atherosclerosis, and cancer. As
an epidemic of obesity spreads across the globe, a better under-
standing of how obesity develops and contributes to associated
diseases is an imperative public health objective.
A major advance in understanding the molecular mechanisms
of obesity was the discovery of leptin. An adipokine, leptin is
secreted by adipocytes and communicates energy needs to
the central nervous system. After feeding, leptin release signals
satiety to the hypothalamus, triggering loss of appetite and
appropriate energy storage in the liver and muscle. Thus, mice
deficient in leptin exhibit voracious appetite and unregulated
glucose production despite feeding. These mice rapidly gain
weight, leading to morbid obesity at only 4 weeks of age (Zhang
et al., 1994). In cases of diet-induced obesity, excess metabo-
lites and lipid consumed in diet result in high levels of circulating
leptin, but dysregulated leptin signaling maintains adipocyte
hypertrophy and obesity. The mechanism of leptin dysregulation
in obesity remains unclear.
For years, genome-wide association studies have sought to
identify obesity susceptibility genes. Recent studies of gene
expression networks of adipose tissue of obesemice and human
subjects have revealed extensive inflammatory gene networks
associated with obesity. Two recent reports took unbiased
approaches to investigate how complex gene expression
networks vary in obese and lean subjects. Obesity-associated
traits including body mass index (BMI) and body fat percentage
were correlated with gene transcripts from hundreds of human
adipose tissue samples (Emilsson et al., 2008). The transcrip-
tional program in obese adipose tissue contained a single
module of coexpressed genes that was found to overlap with
a murine genetic network defined in a companion report (Yang
et al., 2009). In this study, gene networks in liver and adipose
tissue perturbed by loci conferring susceptibility to metabolic
syndrome were used to define an expression module highly
enriched in genes controlling inflammation, immunity and
macrophage activation (Chen et al., 2008).
The mechanistic link between these macrophage gene
networks and obesity is not clear. However, a few possibilities
that have emerged in recent literature may provide clues to
how the immune system can influence the development of
obesity. First, central nervous system inflammation may directly
facilitate diet-induced obesity. Second, although controversial,
TLR4 may directly contribute to the development of obesity,
particularly in the context of diets high in saturated fats (Nguyenand Sok, 2004; Tsukumo et al., 2007). Third, the established
association of gut microbiota with obesity (Ley et al., 2006) is
supported by recent findings causally linking innate immunity
to obesity through the regulation of gut microbiota (Vijay-Kumar
et al., 2010). The growing body of work reviewed below suggests
that not only does overnutrition promote inflammation, but that
the immune system may at least be complicit, if not directly
involved, in the development of obesity as well.
Inflammation in Obese Adipose Tissue
Obesity is associated with chronic activation of inflammatory
pathways in both adipocytes and in macrophages residing in
or infiltrating the adipose tissue. Adipocytes are not only lipid
storage depots, but also secretory cells that produce proinflam-
matory cytokines and adipokines. Adipocytes monitor energy
storage levels and release proinflammatory cytokines to report
overnutrition to the rest of the body. Adipocytes from obese
mice produce the chemokines and cytokines such as MCP-1,
MIPs, IL-6, IL-1b, and TNF-a. Together, these proinflammatory
mediators recruit monocytes into adipose tissue and activate
their differentiation to M1 macrophages (Xu et al., 2003). Adipo-
cytes also release adipokines such as Sfrp1 that counter proin-
flammatory signaling (Ouchi et al., 2010). Compared to lean
mice, the adipose tissue of obese mice is greatly enriched in
proinflammatory M1 macrophages. The fraction of adipose
tissue that is adipose tissue macrophage (ATM) of the M1 type
increases commensurately with the severity of obesity, and
can be up to 40% in obese mice (Weisberg et al., 2003; Lumeng
et al., 2007a, 2007b). It should be noted that similarities between
adipocytes and macrophage cells might obscure the source of
inflammatory mediators in the adipose tissue. Both cells can
consume lipid, and lipid-engorged macrophage cells may be
difficult to distinguish from adipocytes in some cases (Weisberg
et al., 2003). Intermuscular adipose tissue also contains signifi-
cant numbers of macrophages, which increase in frequency in
obese mice (Weisberg et al., 2003) and are of the proinflamma-
tory M1 type (Nguyen et al., 2007; Patsouris et al., 2008).
A number of recent reports have suggested that T lympho-
cytes play an important role in the production of proinflammatory
cytokines and recruitment of macrophage to obese adipose
tissue. Like monocytes, T cells circulate through the body and
infiltrate peripheral tissues in response to chemokine and cyto-
kine signals. Infiltrating lymphocytes precede macrophage pop-
ulations in response to high-fat diet andmay therefore provide an
important source of proinflammatory mediators to promote
macrophage recruitment and activation. Cytotoxic T lympho-
cytes of the CD8 lineage are greatly enriched in the adipose
tissue of mice fed a diet high in fat, a finding consistent with
increased CD8 cells in obese human patients (Nishimura et al.,
2009). Mice deficient in CD8 cells were partially protected from
diet-induced obesity, whereas adoptive transfer of CD8 cells
aggravated adipose inflammation (Nishimura et al., 2009). In
another recent study, a unique pattern of TCRs was identified
among adipose tissue T cells of obese mice, a subset of the
full TCR repertoire in this tissue (Yang et al., 2010). Skewing of
T cell populations and TCR suggests T cells contribute to inflam-
mation in obesity.
Populations of CD4+Foxp3+ Tregs are also altered as CD8
effectors increase in obese adipose tissue. Tregs are highly en-
riched in adipose tissue of normal mice (Feuerer et al., 2009).Cell Metabolism 13, January 5, 2011 ª2011 Elsevier Inc. 13
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mokines and chemokine receptors, integrin adhesionmolecules,
and components of the IL-10 anti-inflammatory pathway. Intrigu-
ingly, restricted TCR diversity was found in adipose tissue Tregs,
as well (Feuerer et al., 2009). Altered selection of Treg TCRs,
through the recognition of cognate antigen, suggests that both
Tregs and effector T cells of the adaptive immune system partic-
ipate in the development of metabolic inflammation. Indeed,
unlike normal mice, Tregs were lost from the abdominal adipose
tissue in obese mice (Feuerer et al., 2009). These data suggest
that Tregs may repress adipose tissue inflammation directly in
nonobese animals, yet the mechanism of Treg dysregulation in
obesity is unclear.
What triggers the inflammatory response in adipose tissue
remains unknown. The prevailing hypothesis is that adipocyte-
generated cytokines recruit monocytes and T cells to the obese
adipose tissue and promote the differentiation of monocytes to
M1 macrophage to initiate systemic inflammation. But what
induces inflammation in adipose tissue? It is agreed that meta-
bolic stress, both the extracellular and intracellular buildup of
metabolites from overnutrition, can activate inflammatory path-
ways. For instance, an excess of metabolic building blocks in
the endoplasmic reticulum (ER) or increased levels of unmetab-
olized free fatty acids can initiate inflammatory pathways in
a variety of cell types. Alternatively, increased adipocyte death
in obese tissue could recruit macrophages to clear away dead
cells. Indeed, adipose tissue macrophages organize crown-like
structures around necrotic cells, thereby forming a locus of
chronic inflammation (Medina-Gomez et al., 2007). In yet another
potential mechanism, the possible ligation of Toll-like receptors
on adipocytes or macrophages by dietary lipids could exploit
the canonical inflammatory signaling pathway to activate
NF-kB and produce inflammatory mediators. The reports dis-
cussed below employ mouse genetic models in which signaling
pathways responsible for coupling nutrient excess to inflamma-
tion during obesity were interrogated.
The noncanonical IKK kinase IKK3 was recently shown to be
required for high-fat diet-induced obesity (Chiang et al., 2009).
IKK3 is not expressed in most resting cells, but is transcription-
ally induced by NF-kB downstream of inflammatory stimuli.
IKK3 contributes to the late phase of the NF-kB transcriptional
activity but primarily plays an important role in interferon
signaling, and is therefore required to combat certain viral infec-
tions (Adli and Baldwin, 2006; Tenoever et al., 2007). IKK3
expression is dramatically upregulated in response to nutrient
excess, up to 40-fold in adipocytes and fat-infiltrating macro-
phages (Chiang et al., 2009). IKK3 deficiency uncoupled obesity
from high-fat diet by increasing energy usage, oxygen respira-
tion, and thermogenesis. In part as a likely consequence of
reduced weight gain and perhaps also due to direct defects in
cytokine production and signaling, IKK3 knockout (KO) mice
were protected against diet-induced insulin resistance, chronic
inflammation in liver and fat, and activation of additional proin-
flammatory pathways. Therefore, IKK family signaling has
a crucial role in both overnutrition-driven obesity and metabolic
disease.
Extensive research has shown that the IKKg/IKKb complex
activates NF-kB-mediated gene expression downstream of
TLRs and cytokine receptors (Hayden and Ghosh, 2008). To14 Cell Metabolism 13, January 5, 2011 ª2011 Elsevier Inc.investigate whether canonical NF-kB signaling pathways are
responsible for inflammation associated with obesity, mice defi-
cient in IKKb in individual tissue compartments and cell types
were evaluated. Using this approach, expression of IKKb in
both the liver and in myeloid cells was shown to be dispensable
for induction of obesity by a high-fat diet or leptin deficiency
(Arkan et al., 2005). These findings suggested that although
inflammation is required for perturbation of central metabolism
by nutrient excess, inflammatory signaling pathways in individual
tissues of the liver and macrophages can be bypassed during
systemic overnutrition and development of obesity in mice.
Central Nervous System Inflammation and Obesity
Overnutrition-associated chronic inflammation also affects
metabolic regulation in the central nervous system (CNS). The
mediobasal hypothalamus regulates energy balance and
prevents obesity by adjusting appetite and food intake in
response to signals of metabolic status including insulin and
leptin. To investigate how inflammatory gene expression contrib-
utes to central control of nutrient metabolism, the Cai group
sought to define IKKb action in the hypothalamus. IKKb is consti-
tutively expressed in the hypothalamus and directs NF-kB acti-
vation in the CNS of mice exposed to a high-fat diet (Zhang
et al., 2008). Forced expression of IKKb in the CNS interrupted
leptin and insulin signaling, resulting in increased intake of
high-fat food and weight gain compared to WT mice. By
contrast, targeted disruption of IKKb in the hypothalamus low-
ered food intake and protected mice from obesity as well as
diet-induced insulin resistance and glucose intolerance (Zhang
et al., 2008).
IKKb activity in the CNS was associated with augmented IL-6
production, and JNK and cytokine signaling, suggesting that
NF-kB target genes mediate the metabolic changes observed
in the CNS of IKKbKO animals. Several reports have linked over-
nutrition with stressed protein assembly pathways in the ER
leading to inflammation and even the development of hepatic
insulin resistance (Hotamisligil, 2010; Ozcan et al., 2009; Sabio
et al., 2008; Ozcan et al., 2004). Pharmacological inhibition of
ER stress pathways diminished NF-kB activation by high-fat
diet (Ozcan et al., 2004; Ozcan et al., 2006). IKKb interfered
with leptin signaling in the brain, food intake, and body weight,
indicating that NF-kB coordinates metabolic stress responses
to overnutrition in noncanonical cell types.
NF-kBactivation by overnutrition also results fromdetection of
extracellular inflammatory triggers by classical inflammatory
pathways. TLR4 recognition of LPS molecules on the outer
membrane of gram-negative bacteria initiates a robust innate
immune response through NF-kB. In a highly interesting obser-
vation, nutritional free fatty acids were found to activate signaling
downstream of TLR4 (Shi et al., 2006). TLR4 deficiency uncou-
ples lipid excess and high-fat diet from inflammatory signaling
in adipocytes, insulin resistance in the muscle, and glucose
intolerance (Shi et al., 2006). A loss of function mutation in
TLR4 protects against insulin resistance in adipose tissue as
well as diet-induced obesity (Poggi et al., 2007; Tsukumo
et al., 2007; Davis et al., 2008). A similar role to that of TLR4
has also been reported for TLR2. Activation of ATM through
either TLR4 or TLR2 in response to free fatty acids induces
inflammatory cytokine production and promotes local insulin
resistance (Nguyen et al., 2007). Mice lacking TLR2 are
ER stress TLR signals
leptin
obesity
IKK
Figure 2. Overweight and Obesity Induces Activation of
Inflammatory Mediators in Adipocytes and Infiltrating Macrophage
Cells
Metabolism of excess nutrients imposes stress on adipose tissue. Production
of proinflammatory cytokines by adipocytes and adipocyte hypertrophy and
expiration recruits M1 proinflammatory macrophages into the adipose tissue.
Proinflammatory signaling in central nervous system andmacrophage-derived
cytokines promote systemic dysregulation of leptin signaling and perturbed
energy balance.
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and display reduced inflammatory cytokine expression (Davis
et al., 2010). How dietary lipids, often oxidized and rendered
more immunogenic by overnutrition, activate NF-kB remains
incompletely understood. Recent studies have demonstrated
that excess nutritional fatty acids can be sensed by TLR2/4,
triggering activation of IKKb andNF-kB, as well as JNK and other
TLR-activated pathways, in a MyD88-dependent manner both in
hematopoietic cells and in the CNS.
The adaptor molecule MyD88 associates with the cytoplasmic
domains of TLRs to organize the initiation of a signaling cascade
(Figure 1). MyD88-deficient mice uncouple TLR4 ligation from
activation of NF-kB and the innate immune response to bacterial
pathogens. A recent study found mice containing a targeted
deletion of MyD88 exclusively in the CNS were protected from
obesity and leptin resistance induced by dietary lipids or
a high-fat diet (Kleinridders et al., 2009). CNS-specific MyD88
KO mice respond to high-fat diet by reducing food intake to
maintain bodyweight, insulin responsiveness, and glucose toler-
ance. Interestingly, activation of ER stress mediators including
JNK was equivalent in MyD88 KO and WT mice. Likewise,
inflammatory mediators TNF-a and IL-6 were not downregulated
in the CNS-specific MyD88 KO mice. The authors therefore
postulate that, rather than ER or inflammatory mechanisms,
direct TLR4 ligation by oxidized lipids stimulates MyD88-depen-
dent activation of IKK without activating a secondary cytokine
signaling cascade. In a similar finding, TLR4 mutant mice
uncouple high-fat diet from obesity and metabolic syndrome,
as discussed later in this review (Tsukumo et al., 2007). How
LPS or other TLR triggers might access the CNS is not known.
Yet free fatty acids may induce NF-kB to disrupt leptin signaling
in the CNS during nutrient excess.
TLRs, Gut Microbiota, and Obesity
TLRs themselves play important roles in the development of
obesity. A significant factor in the relationship between inflam-
mation and obesity is the influence of TLRs on the gut micro-
biota. It has long been known that the gut flora of obese patients
differ dramatically from healthy ones: circulating LPS is dramat-
ically elevated in obese patients compared to lean patients.
A recent study demonstrates that mice deficient in TLR5
possess unique gut microflora that sensitize them to obesity
andmetabolic syndrome (Vijay-Kumar et al., 2010). Remarkably,
transfer of the gut flora from TLR5 KO animals to lean recipients
recapitulates an obese phenotype. Yet whereas TLR5 deficiency
in the gut permits outgrowth of pro-obesity flora, TLR4
deficiency in hematopoietic cells reduces inflammatory signaling
required for diet-induced insulin resistance. With a bone marrow
transfer system, TLR4-deficient macrophages were shown to
protect against diet-induced insulin resistance (Saberi et al.,
2009). These studies suggest that innate immune receptors
influence immunity in numerous ways in different cell types,
underscoring a potential role for NF-kB and the immune system
in the development of obesity (Figure 2).
While growing evidence suggests that inflammatory signaling
pathways can contribute to obesity, it remains unclear how the
two processes are linked. A global mechanism whereby excess
metabolites induce CNS inflammation via IKK and ER stress is
supported by studies of another positive regulator of NF-kB,
3-phoshoinositide dependent kinase 1 (PDK-1). Mice in whichPDK-1 was specifically inactivated in pro-opiomelanocortin
CNS cells demonstrate altered energy balance and increased
adiposity compared to WT mice (Belgardt et al., 2008). More-
over, selective ablation of JNK in the CNS normalizes adiposity
in mice subjected to a high-fat diet (Belgardt et al., 2010). The
role of NF-kB was not examined in these reports, and signaling
crosstalk to IKK may underlie the effects of ER stress on pro-
inflammatory signaling. Alternatively, PAMP receptors and
oxidized lipids could activate IKK via MyD88. Or both mecha-
nisms may operate in the CNS, collaborating to activate IKK
and NF-kB during nutrient excess and obesity (Figure 3).NF-kB, Insulin Resistance, and Type 2 Diabetes
Insulin resistance and type 2 diabetes now affect over 60 million
Americans and are predicted to be the leading killer worldwide
by 2050. Type 2 diabetes begins with insulin resistance, the
impaired responsiveness of target organs to circulating insulin.
An anabolic hormone released by beta (b) cells in the pancreas,
insulin regulates energy metabolism in liver, skeletal muscle and
adipose tissues. Ligation of the insulin receptor in target cells
induces tyrosine phosphorylation of insulin receptor substrates
and a signaling cascade to direct changes in energy metabo-
lism. Excess glucose and lipid metabolites impair insulin sensi-
tivity, causing desensitized signaling from the insulin receptor,
abnormal translocation of glucose transporters, and altered
activities of intracellular glucose metabolism enzymes. Because
insulin promotes glucose uptake in the muscle and reduces
gluconeogenesis in the liver and lipolysis in adipose tissue,
insulin resistance results in defective nutrient metabolism and
glucose intolerance. With increasing insulin resistance in
muscle, liver and adipose tissues, there comes a point at which
pancreatic b cells can no longer compensate by secreting moreCell Metabolism 13, January 5, 2011 ª2011 Elsevier Inc. 15
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Figure 3. TLR and ER Stress Responses in Insulin Resistance
Signaling from cytokine receptors and Toll-like receptors on the cell surface,
as well as ER stress, can activate the IKK complex and NF-kB to activate
expression of proinflammatory cytokines and disable insulin signaling. Defec-
tive insulin signaling contributes to insulin resistance and the development of
type 2 diabetes.
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develops.
Insulin resistance and type 2 diabetes are now recognized as
chronic inflammatory diseases. As b cells in the pancreas work
to produce more and more insulin, metabolic stress signals
recruit monocytes to clear dying b cells. These recruited mono-
cytes differentiate into TNF-a-, IL-6-, and IL-1-producing macro-
phages that promote further b cell dysfunction and death. TNF-a
disrupts insulin signaling and sensitivity (Hotamisligil et al., 1993).
Elevated levels of TNF-a are detected in the bloodstream and in
the peripheral tissues of insulin-resistant mice (Hotamisligil et al.,
1993). Insulin-responsive cells including adipocytes and hepato-
cytes produce TNF-a, IL-6, and IL-1, and both tissue and circu-
lating cytokine levels are increased by a high-fat diet. In mice,
both TNF-a neutralization and deficiency each prevent high-fat
diet-induced insulin resistance (Hotamisligil et al., 1993; Uysal
et al., 1997).
The role of NF-kB in the pathology of type 2 diabetes was first
suggested when aspirin and other salicylates, used extensively
in the early 20th century to treat rheumatic disease, proved bene-
ficial in patients with glucose intolerance (Williamson, 1901; Ho-
tamisligil and Erbay, 2008). The discovery that salicylates target
NF-kB (Kopp and Ghosh, 1994) was followed by the demonstra-
tion that insulin resistance is effectively reversed by high-dose
salicylates in murine models of obesity (Yuan et al., 2001). In
a landmark study,mice heterozygous for IKKb (Ikk2+/) were pro-
tected against insulin resistance from both diet-induced and
genetic obesity (Yuan et al., 2001). Finally, salicylates, which
may directly target IKKb within the NF-kB pathway (Yin et al.,
1998), were also shown to inhibit fat-induced insulin resistance
in skeletal muscle (Kim et al., 2001; Yuan et al., 2001). Together,
these findings suggest that IKKb is not only an essential mediator
of obesity-induced diabetes but also a promising therapeutic
target for insulin resistance and glucose intolerance. They also
raise the question of whether NF-kB activity is directly respon-
sible for diet-induced insulin resistance. Because NF-kB path-16 Cell Metabolism 13, January 5, 2011 ª2011 Elsevier Inc.ways are activated in a variety of cell types at different stages
of insulin resistance, follow-up studies sought to address the
signaling pathways and cell types responsible for IKKb-medi-
ated metabolic disease.
The liver is a vital tissue in energymetabolism, the site of amino
acid, glucose, and lipid biosynthesis. In hepatocytes, insulin
signaling causes the arrest of gluconeogenesis and increased
storage of glucose as glycogen. Expression of constitutively-
active (CA) IKKb in the liver resulted in defective insulin signaling
in hepatocytes andmuscle cells, elevated resting levels of insulin
and free fatty acids, and systemic insulin resistance and glucose
intolerance (Cai et al., 2005). Interestingly, although nutrient
excess can be sensed in various tissues, IKKb activation in liver
was able to communicate overnutrition pathways to peripheral
tissues. IKKb activation was associated with increased expres-
sion of NF-kB target genes including IL-6. IL-6 blockade
reversed CA-IKKb-induced inflammation in both liver and in
muscle, supporting a role for proinflammatory cytokines in the
transmission of insulin resistance among tissues (Cai et al.,
2005). Although muscle is clearly an essential insulin-responsive
tissue (Petersen & Shulman, 2006), constitutively active IKKb in
muscle produced severe muscle wasting but no change in
insulin signaling (Cai et al., 2004). However, deletion of IKKb
inmacrophages protectedmice from the development ofmuscle
insulin resistance in the context of obesity (Arkan et al., 2005).
These results suggest that NF-kB activation in ATM of both
muscle and liver adipose tissue can contribute to development
of insulin resistance in these tissues in the context of obesity.
Unregulated expression of IKKb in liver promotes diet-induced
insulin resistance. For determination of whether IKK is required
for diet-induced insulin resistance, IKKbwas specifically deleted
in the liver. Liver-specific ablation of IKKb protectedmice against
diet-induced insulin resistance and glucose intolerance among
hepatocytes and reduced lipid deposition in liver (Arkan et al.,
2005). Yet despite local glucose tolerance, central insulin
signaling in IKKb liver KO mice remained susceptible to overnu-
trition: muscle and adipose tissue developed insulin resistance in
response to high-fat diet, obesity, and aging. Modest decreases
in circulating IL-1b and IL-6 levels suggested that levels of cyto-
kines in the liver are likely to be significantly diminished by the
absence of IKKb. Further studies demonstrating that ablation
of IL-6 in the liver exacerbates obesity-induced insulin resistance
suggest that a fine balance of inflammatory mediators are
required for optimal metabolic control in the liver (Wunderlich
et al., 2010). Together, these findings indicate that although the
proinflammatory signaling pathways initiated by overnutrition in
hepatocytes can be sufficient to induce systemic insulin resis-
tance, IKKb signaling in the liver is not required for insulin resis-
tance, as it can be bypassed by release of pro-inflammatory
mediators by other tissues and cell types.
NEMO (IKKg) expression in the liver is also required for devel-
opment of obesity-induced insulin resistance. Mice deficient in
NEMO in the liver were somewhat protected from diet-induced
obesity, glucose intolerance, and insulin resistance (Wunderlich
et al., 2008). Interestingly, liver NEMO KO caused deposition of
fatty acids in the liver, causing increased hepatocyte death
compared to the WT. Therefore, both proinflammatory and pro-
survival NF-kB functions (Luo et al., 2005) may be activated
alongside each other during overnutrition. This synergy may
macrophage
liver
muscle
adipose tissue
Figure 4. Macrophage Cells Are Central Mediators of Insulin
Resistance
Nutrient excess is sensed in peripheral metabolic tissues to result in produc-
tion of proinflammatory cytokines IL-6, IL-1, and TNF-a. These cytokines drive
macrophage activation and propagation of proinflammatory signals
throughout the organism.
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(Calle et al., 2003), although different nutritional states and TLR
signaling mechanisms are also likely at play.
Analyses of IKK action in the liver suggested that proinflamma-
tory signaling initiated by overnutrition in insulin-sensitive tissues
requires propagation by additional cell types to produce
a systemic inflammatory response. Monocytes circulate through
the bloodstream and tissue, where they sense cytokines through
surface receptors and secrete large amounts of cytokines upon
activation. Macrophage infiltration of the pancreas and adipose
tissue is associated with the development of insulin resistance.
So that the requirement for myeloid inflammation in insulin resis-
tance could be determined, IKKb was deleted in monocytes.
Myeloid IKKb KO mice uncoupled overnutrition by high-fat diet
or genetic obesity from proinflammatory pathways, protecting
mice from insulin resistance and glucose intolerance in all
insulin-sensitive tissues (Arkan et al., 2005). Thus, while liver
may provide an initial source of inflammatory mediators directly
affecting liver insulin resistance, NF-kB signaling in specialized
innate immune cells, the ATMs, is required to propagate these
signals to the rest of the organism and promote systemic insulin
resistance in muscle and other normally insulin-sensitive tissues
(Figure 4).
T lymphocytes may collaborate with monocytic leukocytes to
regulate insulin responsiveness during diet-induced obesity.
Lymphocytes regulatemacrophage differentiation and activation
byproducing IL-6 andTNF-a. Obeseadipose tissue is enriched in
CD8 cytotoxic T lymphocytes and Th1-type helper CD4 T cells
and depleted in CD4+CD25+ regulatory T cells (Feuerer et al.,
2009; Nishimura et al., 2009; Yang et al., 2010). Additionally,
IFNa-producing Th1 CD4 helper T cells infiltrate adipose tissue
of mice on a high-fat diet (Winer et al., 2009). T cell deficient
Rag/ animals appear to be hypersusceptible to diet-induced
obesity and insulin resistance, suggesting that T cells mediate
inflammation resulting in obesity and metabolic disease.
Restoration of energy balance in Rag/ mice by adoptive
transfer of CD4+Foxp3+ Tregs suggested that Tregs promote
glucose tolerance, insulin sensitivity, and diminished weight
gain despite a diet high in fat. Induction of Tregs with TGF-b alle-
viated insulin resistance and glucose intolerance through IL-10,
providing further support for immunosuppression by Tregs and
IL-10 in insulin-sensitive tissue (Ilan et al., 2010). The finding that
both effector and regulatory CD4 T cells attenuate inflammatory
signaling in adipose tissue suggests that the adaptive immune
system is intimately intertwinedwith the progression ofmetabolic
disease. Although overnutritionmay generatemolecules capable
of driving TCR-specific T cell activation and expansion, the iden-
tities of such specific metabolic antigens remain obscure.
Studies of genetic mutant mice demonstrate an essential role
for NF-kB in the inflammatory response required for the develop-
ment of insulin resistance. Yet, NF-kB controls the expression of
wide array of target genes, including many that regulate cell
growth and survival. Prosurvival functions of NF-kB also
contribute to insulin sensitivity in pancreas. During the onset of
insulin resistance, b cells grow and expand in an NF-kB-depen-
dent manner to compensate for insulin insensitivity in individual
cells. Furthermore, as insulin insensitivity and b cell stress
increases production of inflammatorymediators, NF-kBprotects
pancreatic b cells from TNF-a-mediated apoptosis (Chang et al.,2003). In spite of these functions, NF-kB blockade can protect
pancreatic islets from diabetogenic agents (Eldor et al., 2006).
In a similar finding, an NF-kB superrepressor protected pancre-
atic islet cells from IL-1b-induced cell death (Giannoukakis et al.,
2000). NF-kB may also regulate normal glucose uptake and
insulin secretion. Specific attenuation of NF-kB activation in
b cells diminished glucose-stimulated insulin secretion (Norlin
et al., 2005). Together, these reports suggest that multiple func-
tions of NF-kB operate in b cells and that their contribution to
insulin resistance depends on both inflammatory and cell
survival signaling pathways.NF-kB Function in the Development of Atherosclerosis
In addition to their role in insulin resistance in both liver and
adipose tissue, proinflammatory pathways regulated by NF-kB
also contribute to vascular disease associated with metabolic
excess. Atherosclerosis is a disease of the arterial wall, now
recognized to be driven by inflammatory processes (Rocha
and Libby, 2009). Atherosclerosis begins when excess unmetab-
olized lipoproteins collect in the bloodstream. Oxidized lipopro-
teins trigger secretion of chemokines MIP-1a and MCP-1 by
vascular endothelia, recruiting leukocytes to the site of inflam-
mation (Weisberg et al., 2006). There, adhesion molecules
ICAM-1 and VCAM-1 on the vascular surface promote slow roll-
ing and arrest of circulating monocytes on the vascular wall.
Once in contact with vascular endothelia, monocytes differen-
tiate intomacrophages, ingest deposited lipoproteins to become
foam cells, and create a site of local inflammation. Macrophage
foam cells secrete IL-6, TNF-a, and other cytokines to recruit
more immune cells, resulting in the formation of atherosclerotic
plaques (Figure 5). These lesions, containing lipid molecules
and immune cells, narrow the arterial wall and promote cardio-
vascular disease and thrombosis.
NF-kB integrates multiple processes in the formation of
atherosclerotic plaques. NF-kB controls expression of genesCell Metabolism 13, January 5, 2011 ª2011 Elsevier Inc. 17
Figure 5. NF-kB Mediates Proinflammatory Signaling in Endothelia and Leukocytes that Drives Atherogenesis
Proinflammatory signaling networks through NF-kB in vascular endothelia respond to deposition of oxidized lipoproteins by expression of adhesionmolecules on
the cell surface and leukocyte cytokines. Circulating monocytes are arrested at the site of inflammation and differentiate into cytokine-producing macrophage
cells. Macrophage cells also consume lipids on the vascular wall swelling into foam cells that nucleate the atherosclerotic plaque. Continued recruitment, acti-
vation of leukocytes, lipid consumption, and cell death results in the formation of a large atherosclerotic lesion impairing arterial blood flow and promoting throm-
bosis.
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including cytokines TNF-a, IL-1b, IL-6, chemokine MCP-1, and
the adhesion molecule ICAM-1. The detection of NF-kB in nuclei
of macrophages in atherosclerotic lesions (Brand et al., 1996)
suggests that NF-kBactivation is associatedwith atherogenesis.
Together, numerous genetic studies reveal a sophisticated role
for NF-kB in the pathology of atherosclerosis, in which different
mechanisms and cell-specific actions coordinate its initiation,
progression, and resolution.
Because inflammatory programs in both endothelia and re-
cruited myeloid cells contribute to atherotic plaques, numerous
studies have set out to define the individual contribution of
each cell type in atherogenesis. Mice deficient in apolipoprotein
E (ApoE), a ligand important in lipoprotein clearance, exhibit
greatly elevated levels of circulating very low-density lipoprotein
(VLDL) cholesterol. Because hyperlipidemia accelerates the
formation of atherosclerotic plaques, these mice are commonly
employed to model atherosclerosis (Plump et al., 1992; Zhang
et al., 1992). Mice deficient in the receptor for low-density lipo-
protein (LDLR) are predisposed to atherosclerosis for similar
reasons (Ishibashi et al., 1993).
Hyperlipidemic mice were used to investigate the requirement
for IKK-mediated NF-kB activation in endothelial cells in athero-
genesis (Gareus et al., 2008). Nemo deletion in vascular endo-
thelial cells by Tie2-CRE protects against atherosclerosis
induced by high-fat diet in Apoe/ mice. Endothelial Nemo
deletion abrogated expression of adhesion molecules ICAM-1
and VCAM-1. Diminished expression of cytokines TNF-a,
IL-1b, and IL-6 and chemokines MIP-1a and MCP-1 by NEMO-
deficient endothelial cells also reduced infiltration of bothmacro-
phage and T lymphocytes into atherosclerotic plaques.
Together, decreased expression of adhesion molecules and
proinflammatory mediators reduced both the size and severity
of lesions in endothelial NEMO-deficient animals. These findings
support an essential role for NF-kB signaling in vascular endo-
thelial cells in atherosclerosis initiation, as both macrophage
recruitment and plaque formation were greatly reduced when
the NF-kB inflammatory program is disabled in these cells.
As described above, macrophages play an essential role in
communicating inflammation among metabolic tissues in
response to overnutrition and insulin resistance. Type I interferon
signaling promotes macrophage recruitment and accumulation18 Cell Metabolism 13, January 5, 2011 ª2011 Elsevier Inc.within the atherosclerotic plaque and is required for atheroscle-
rosis in Ldlr/ mice (Goossens et al., 2010). Yet the role of
NF-kB-mediated inflammatory functions by macrophage cells
in atherosclerosis remains unclear. Bone marrow transplant
studies found that hematopoietic cells deficient in the NF-kB
subunit p50 diminished number and decreased size of athero-
sclerotic lesions in Ldlr/ mice (Kanters et al., 2004). Surpris-
ingly, lesions in hematopoietic p50 knockout mice exhibited
a highly inflammatory phenotype indicating intact production of
proinflammatory cytokines. Lesions in these mice exhibited
a near complete absence of foam cells, supporting previous find-
ings that NF-kB targets mediate lipid ingestion by macrophage
scavenger receptors and foam cell biogenesis (Ferreira et al.,
2007). Yet how p50 and other NF-kB family members cooperate
to support proinflammatory macrophage function in atherogen-
esis remains to be established. Metabolic stress in lipid-
consuming macrophages has been proposed to drive cell death
and plaque formation. Indeed, pharmacological inhibition of ER
stress uncouples high-fat diet from atherosclerosis, implicating
metabolic stress in the development of atherosclerosis (Erbay
et al., 2009).
In addition to control of inflammatory cell activation, NF-kB
plays an important role in cell survival. Inmacrophage foam cells,
whose necrotic death creates the core of atherosclerotic pla-
ques, the proinflammatory and prosurvival functions of NF-kB
may act at cross-purposes. Using Apoe/ or Ldlr/ models,
several studies have shown that IKKb deletion from the myeloid
compartment fails to prevent atherogenesis in mice fed a high-
fat diet and, instead, increased atherosclerosis in LDLR-deficient
mice (Kanters et al., 2003). However, incomplete deletion of
IKKb, and a 50% reduction of both NF-kB protein and activity
may factor into these observations. Completely ablated expres-
sion of IL-10, in contrast to only modestly reduced IL-6 expres-
sion, suggests that different thresholds for NF-kB target genes
may underlie the described knockout phenotypes.
Furthermore, NF-kB prosurvival functions may also contribute
to development of atherosclerosis in IKKb myeloid KO mice.
Severe atherosclerosis results when foam cells unable to clear
accumulated lipids perish within the necrotic core of an atherotic
plaque. Absent prosurvival functions of IKKb and NF-kB in lipid-
engorged foam cells, increased and unregulated foam cell death
likely facilitates necrosis within the plaque. The relative threshold
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although NF-kB action in endothelial cells and macrophage
foam cells drives the production of proatherogenic cytokines,
its prosurvival functions and its role in the resolution of inflamma-
tion appear to limit plaque size and inflammatory pathology in
mouse models of atherosclerosis. Future studies will define
which NF-kB family members, target genes, and functions in
which cell types coordinate the formation of the necrotic core
and the destructive consequences of chronic inflammation.
In further evidence that NF-kB critically regulates atherogen-
esis, the negative regulator of NF-kB, A20 (tnfaip3) was mapped
to a locus conferring sensitivity to atherosclerosis (Idel et al.,
2003). Indeed, mice haploinsufficient for A20 (tnfaip3+/)
exhibited increased atherotic lesion size among mice deficient
in ApoE. Enforced expression of A20 decreased lesion size
compared to the WT, indicating that NF-kB attenuation by A20
exerts an antiatherogenic function in mice (Wolfrum et al.,
2007). A20 haploinsufficiency was associated with increased
expression of proatherogenic NF-kB target genes including
VCAM-1, ICAM-1, M-CSF, and proinflammatory cytokines
known to promote atherosclerosis (Wolfrum et al., 2007). It
remains unclear whether A20-regulated signaling in endothelial
cells, foam cells, undifferentiated monocytes, or in all of the
above is responsible for attenuating inflammatory atherogen-
esis. Nevertheless, these findings demonstrate that IKK
signaling to NF-kB can be proatherogenic and that modulation
of the NF-kB expression programs offers potential in treating
atherosclerosis and cardiovascular disease.
Concluding Remarks
NF-kB signaling in numerous cell types contributes to the
pathology of metabolic disorders. Resident tissue cells activate
NF-kB in response to stress associated with nutrient excess.
Vascular endothelia induce NF-kB in response to binding
oxidized lipids in the bloodstream. Specialized cells of the meta-
bolic system including hepatocytes, adipocytes, and neurons in
the hypothalamus induce NF-kB in response to overnutrition,
perhaps in response to metabolic or oxidative stress in the ER.
Increased metabolic demands can induce necrotic cell death,
itself a proinflammatory signal to NF-kB activation. And lastly,
activation of innate immune receptors such as TLR4 through
MyD88 could activate NF-kB in response to an excess of free
fatty acids in a high-fat diet.
It is clear that NF-kB inflammatory pathways promote meta-
bolic disease, and therapeutic strategies might directly target
macrophage IKK and NF-kB target genes. Although inhibitors
of specific NF-kB pathways are not yet clinically available, there
continues to be progress in the development of more selective
anti-NF-kB pharmaceuticals and understanding of the effects
of existing therapies on the NF-kB pathway. NF-kB underlies
the most prevalent type 2 diabetes therapeutic treatment thiazo-
lidinedione (TZD) which targets the nuclear hormone receptor
peroxisome proliferator-activated receptor gamma (PPARg)
and promotes insulin sensitivity in macrophages and adipocytes
(Hevener et al., 2007). Blocking the action of inflammatory medi-
ators is currently an attractive therapeutic approach. Although
TNF-a blockade failed to alleviate insulin resistance in human
patients (Martı´nez-Abundis et al., 2007; Dominguez et al.,
2005), this failure may have resulted from insufficient penetrationinto the peripheral tissues. Treatment with IL-1bR antagonist
reversed insulin resistance and glucose intolerance in diabetes
patients (Sauter et al., 2008; Larsen et al., 2007). In a reprise of
classical discoveries, recent clinical trials have found significant
amelioration of insulin resistance and glucose homeostasis in
human type 2 diabetes patients treated with salicylates, which
have been reported to inhibit NF-kB activation (Goldfine et al.,
2010; Fleischman et al., 2008).
Together, these studies demonstrate that interfering with
NF-kB-driven inflammation can alleviate type 2 diabetes in
patients and decrease hyperglycemia and insulin resistance.
And yet a mechanistic understanding of how inflammatory
signaling promotes metabolic disease remains tentative. In
particular, the initiating events, those that link metabolic excess
to inflammation are, as of yet, incompletely understood. Under-
standing these events is likely to yieldmore selectively druggable
targets—with the ultimate goal of breaking the link between
obesity and the production of pro-inflammatory cytokines
without broadly crippling the host’s ability to fight disease. The
relatively specialized role of IKK3 in NF-kB signaling may provide
one potential site of intervention. Very recent and exciting work
has uncovered a mechanistic link between the beneficial effects
of omega-3 fatty acids and inhibition of the NF-kB pathway
(Oh da et al., 2010). This work reveals new sites of potential inter-
vention in the pathways between diet, NF-kB, and insulin resis-
tance. Continued investigations into lipid receptors, cell stress
pathways and the networks of inflammatory propagation should
provide new and better targets for therapeutic intervention in the
future.
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